Background and Objective: Antipsychotic polypharmacy (APP) is a controversial topic in the treatment of older adults with schizophrenia. The objective of this study was to examine the use of APP in older adult Asian patients with schizophrenia and its associated demographic and clinical factors. Methods: This study was based on the fourth survey of the consortium known as the Research on Asian Psychotropic Prescription Pattern for Antipsychotics. Fifteen Asian countries/territories participated in this survey, including Bangladesh, Mainland China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Myanmar, Pakistan, Singapore, Sri Lanka, Taiwan, Thailand, and Vietnam. Basic demographic and clinical characteristics were collected using a standardized data collection form. Results: Among the 879 older adults with schizophrenia included in the survey, the rate of APP was 40.5%. Multiple logistic regression analysis revealed that higher antipsychotic doses (P < .001, odds ratio [OR] ¼ 1.003, 95% confidence interval [CI]: 1.002-1.003), longer duration of illness (P ¼ .02, OR ¼ 1.845, 95% CI: 1.087-3.132), and the prescription of anticholinergics (P < .001, OR ¼ 1.871, 95% CI: 1.329-2.635), second-generation antipsychotics (P ¼ .001, OR ¼ 2.264, 95% CI: 1.453-3.529), and first-generation antipsychotics (P < .001, OR ¼ 3.344, 95% CI: 2.307-4.847) were significantly associated with APP. Conclusion: Antipsychotic polypharmacy was common in older adult Asian patients with schizophrenia. Compared to the results of previous surveys, the use of APP showed a declining trend over time. Considering the general poor health status of older patients with schizophrenia and their increased risk of drug-induced adverse events, the use of APP in this population needs careful consideration.
Introduction
Schizophrenia is a severe psychiatric disorder that is associated with functional deficits 1 and increased risk of premature death. 2 Compared to the general population, the mortality rate in patients with schizophrenia is 2 to 3 times higher. 3 With the improvement in general health care, 4 the life expectancy of patients with schizophrenia have increased, and many are living into older adulthood. 5 Compared to their younger counterparts, older patients have poorer physical health, more frequent use of multiple medications, lower pharmacokinetic clearance, and higher risk of drug-drug interactions. 6 These factors may hence increase their susceptibility to antipsychotic-induced side effects. 7 As a result, antipsychotic prescription patterns for older patients with schizophrenia are likely to be different from younger patients.
Most treatment guidelines for schizophrenia recommend antipsychotic monotherapy as the first choice. 8, 9 However, approximately 15% to 39% of patients with schizophrenia do not respond satisfactorily to antipsychotic monotherapy, 10 which may explain why antipsychotic polypharmacy (APP; co-prescription of 2 or more antipsychotics for the same patient) is common in clinical practice. 11 At lower doses, APP could be effective without increasing the risk of side effects. 12 However, APP usually results in excessive antipsychotic doses 13 that is associated with adverse treatment outcomes, 14, 15 such as increased risk of hospitalization, 16 discontinuation rate, 17 mortality, 18 and heavy financial burden. 19, 20 A meta-analysis found that APP may be superior to monotherapy in certain cases, but most patients in the included studies had received clozapine-augmentation treatments.
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Another meta-analysis found that the combination of clozapine and other antipsychotics was superior in open studies compared to double-blinded studies. 22 Despite APP not having any clear benefits in treating schizophrenia, a systematic review found that use of APP was higher in Asia (32%) than in North America (16%) or Europe (23%).
Only a few studies have examined the prescription pattern of APP in older patients with schizophrenia in Asia. Regular surveys of prescription patterns of psychotropic medications are an efficient way to examine the treatment rationale and trends over time. 24, 25 The frequency of APP in older Asian patients with schizophrenia was first reported to be 51.6% in a 2008 study. 26 This updated study examined the rate of APP in older adult patients with schizophrenia in Asia and its associated demographic and clinical factors. It was hypothesized that the rate of APP may be decreasing over time due to the increasing awareness of APP-related adverse effects in this population group. 27, 28 Fifteen Asian countries/territories participated in the REAP-AP4 survey, including Bangladesh, Mainland China (China thereafter), Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Myanmar, Pakistan, Singapore, Sri Lanka, Taiwan, Thailand, and Vietnam. Patients with schizophrenia who received treatment during the study period were consecutively screened and enrolled if they were eligible to participate.
Materials and Methods

Study Design and Patients
The REAP-AP4 survey protocol was approved by the internal review boards of all participating psychiatric units and hospitals. Written informed consent was provided by patients who were interviewed. In line with local ethical standards and regulations, consent was waived at the study sites where data were collected only by a review of medical records. 29 Patients who fulfilled the following criteria were included in the REAP-AP4 survey: (1) diagnosis of schizophrenia according to the International Classification of Diseases, Tenth Revision or Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; (2) treatment with psychotropic medications; (3) inpatients or outpatients; and (4) aged 50 years or older. Patients with severe medical conditions were excluded because they were usually not treated in psychiatric hospitals/units in most Asian countries. Following other studies, 30 ,31 patients aged 50 years or above were classified as "older adults" since patients with schizophrenia are more likely to have premature death. 32, 33 Doses of antipsychotic drugs were converted into chlorpromazine equivalents (CPZeq). 34, 35 Antipsychotic polypharmacy was defined as the concurrent prescription of 2 or more antipsychotic medications. 36 
Data Collection
Following prior REAP surveys, 27,37 basic sociodemographic and clinical characteristics were collected by either a review of medical records or a clinical interview. Type and dose of antipsychotic medications and other psychotropic drugs, psychotic symptoms in the past month, and extrapyramidal symptoms in the past 3 months were recorded. Tardive dyskinesia (TD) was analyzed separately from other types of extrapyramidal symptoms due to its different treatment.
Statistical Analysis
SPSS, version 20, was used in the data analysis. Demographic and clinical variables between the antipsychotic monotherapy (APM) and APP groups were compared using independent sample t test, Mann-Whitney U test for continuous variables, and w 2 test for categorical variables. Binary logistic regression analysis with the "Enter" method was used to explore the independent associations between demographic and clinical variables and APP. The APP was entered as dependent variable, while variables with significance level of < .1 in univariate analyses were entered as independent variables. As there was collinearity between the prescription of first-generation antipsychotic (FGA) and second-generation antipsychotic (SGA), binary logistic regression analysis was performed with FGA and SGA as the independent variable separately. The level of significance was set at .05 (2 tailed).
Results
The demographic and clinical characteristics for the whole sample and separately by APP are presented in Table 1 . Altogether, 879 older adults with schizophrenia were included in this survey. The mean age of the whole sample was 58.0 + 6.7 years (range: 50-87 years). Male gender accounted for 47 (Figure 1 ). Univariate analyses showed significant differences between the APM and APP groups in terms of AP doses, proportion of inpatients, illness duration, positive symptomatology, and the prescription of mood stabilizers, anticholinergics, FGAs, and SGAs. Table 2 shows the results of the country/territory-adjusted regression model after excluding FGA from the independent variables. Higher antipsychotic doses (P < .001, odds ratio Table 3 presents the use of APP and the most frequently prescribed FGAs and SGAs: 5.7% received FGA þ FGA, 22.0% received SGA þ SGA, and 12.9% received FGA þ SGA. The most frequently prescribed SGA was risperidone (32.1%), followed by olanzapine (21.6%), clozapine (16.5%), quetiapine (10.7%), and aripiprazole (5.7%). The most frequently prescribed FGA was haloperidol (10.2%), followed by chlorpromazine (8.0%), flupentixol decanoate (6.3%), fluphenazine decanoate (4.3%), and zuclopenthixol decanoate (3.9%).
Discussion
In this survey, APP was common in older adult patients with schizophrenia in Asia. Altogether 40.5% of the older adult patients received APP, which is considerably lower than previous findings in the REAP surveys (58.4% in 2001, 48 .9% in 2004, and 47.7% in 2009). 26 The decreasing trend of APP in the REAP surveys does not support the notion that polypharmacy would be escalating due to the increasing availability of novel antipsychotics and their clinical prescriptions. 17 The declining trend in this survey may be partly attributed to the growing awareness among psychiatrists in the region about inappropriate use of APP. Compelling evidence showed that younger patients with schizophrenia were more likely to receive APP compared to older patients. 12, 17, 38, 39 One possible reason could be that younger patients usually present with more severe psychotic symptoms in the early stage of schizophrenia, resulting in more frequent use of APP. 17 Moreover, clinicians are usually cautious when prescribing multiple APs to older patients due to the higher risk of medication-induced side effects.
The role of APP in improving psychotic symptoms, psychosocial functioning, and quality of life is still controversial. 21, [40] [41] [42] The APP is usually recommended only after trials of AMP with different APs including clozapine, augmentation strategies with nonantipsychotic medications, and psychosocial interventions have failed. 43 Despite such recommendation in treatment guidelines, 8 APP is common in older adult Asian patients with schizophrenia, even when compared to the rate of APP in younger adult patients with schizophrenia in Western settings: for example, 25.7% in Canada, 16% in North America, and 23% in Europe. 23, 44 The reasons for the high rate of APP in Asia are probably manifold: economic and sociocultural factors in prescribing practice, professional and public attitude toward APP, local prescribing guidelines, and health insurance policies. For example, it is a common perception among clinicians in Asia that combination of medications with different pharmacological properties can be more effective. 45 Psychiatrists in Japan, for instance, were reluctant to change in AMP although 28% of patients on APP were successfully switched to AMP. 46 Further, genetic diversity in pharmacogenetic alleles between Southeast Asian and European populations may also account for interethnic differences in drug response and AP prescription. 47 In this survey, higher AP doses were significantly associated with APP, which is similar to previous findings. 44 More frequent anticholinergic use was positively associated with APP which is probably due to the more frequent and severe extrapyramidal side effects (EPS) induced by APP. 12, 13, 15 Anticholinergics may also increase the risk of cognitive dysfunction and mortality in older patients. 48 There was a positive association between longer illness duration (!5 years) and APP. This may be related to better medication acceptance by patients with a chronic illness 49 and higher likelihood of treatment resistance in patients with a longer illness duration. 50 Compared to previous REAP surveys, the rate of FGA þ FGA prescription (5.7%) has been decreasing (36 26 which is consistent with previous findings. 51, 52 The proportion of FGA þ SGA was 12.9%, which is lower than the earlier REAP figures (19.8% in 2001, 27 .6% in 2004, and 26.2% in 2009). The frequent use of SGAs þ SGAs could be driven by the perceived favorable efficacy of SGAs over FGAs, lower risk of EPS, and the declining costs of SGAs. In addition, the growing use of long-acting depot SGAs could contribute to this trend because they are often prescribed with oral APs. 53 In view of the frequent use of SGAs, the increased risk of metabolic syndrome related to SGAs 20, 54, 55 should be given more attention. 23 The APP is usually associated with excessive AP dosing 13 and increased risk of side effects including metabolic syndrome and EPS. 14, 15 In this study, however, there were no differences between groups in terms of body mass index, acute EPS, and TD.
Of the 5 most commonly prescribed FGAs, 3 were depot APs, which support previous findings that long-acting APs are frequently co-prescribed with oral APs antipsychotics. 53 Given the low cost of FGAs, they are often preferred in several developing Asian countries. 56 In this survey, the most commonly prescribed SGAs in older patients were risperidone and olanzapine. Risperidone appears to be safe in older patients with schizophrenia. 57 In another APP study in the United States, quetiapine and clozapine were the most frequently prescribed SGAs. 58 There are several limitations to this study. First, selection bias could not be avoided as recruitment was done in a consecutive rather than a random fashion. Second, relevant variables related to APP, such as age of onset, severity of symptoms, economic status, and health insurance, were not available in the databases. In addition, diagnoses of severe medical conditions were ascertained by the treating psychiatrists based on the patients/relatives' account rather than systematically collected. Further, since the electronic medical record system in many Asian psychiatric settings contains only the principal diagnosis, the impact of psychiatric comorbidities on APP could not be explored. Due to the cross-sectional design of the REAP-AP surveys, effectiveness and safety of APP could not be determined. Fourth, around half of the sample was recruited from inpatient settings; thus, the findings may not be applicable to community-dwelling patients. In addition, the prescription pattern in this limited sample could not be generalized to prescription practices throughout Asia. Fifth, the rationale for the use of APP could not be explored as this information was not captured in this survey.
In conclusion, the APP in older Asian patients with schizophrenia was common, although there was a decreasing trend over the past 2 decades. Due its uncertain benefits and increased risk of side effects, APP should be cautiously used in the treatment of older patients with schizophrenia. Further research is needed to ascertain the efficacy and risks of APP.
